Should I buy or sell Cogent Biosciences stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" COGT shares. View COGT analyst ratings or view top-rated stocks .

What is Cogent Biosciences' stock price target for 2024?

7 brokerages have issued 1-year price targets for Cogent Biosciences' stock. Their COGT share price targets range from $8.00 to $20.00. On average, they expect the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 103.7% from the stock's current price. View analysts price targets for COGT or view top-rated stocks among Wall Street analysts .

How have COGT shares performed in 2024?

Cogent Biosciences' stock was trading at $5.88 at the beginning of the year. Since then, COGT shares have increased by 14.1% and is now trading at $6.71. View the best growth stocks for 2024 here .

Are investors shorting Cogent Biosciences?

Cogent Biosciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,840,000 shares, an increase of 12.6% from the March 15th total of 9,630,000 shares. Based on an average daily volume of 2,170,000 shares, the short-interest ratio is presently 5.0 days. View Cogent Biosciences' Short Interest .

When is Cogent Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our COGT earnings forecast .

How were Cogent Biosciences' earnings last quarter?

Cogent Biosciences, Inc. (NASDAQ:COGT) posted its earnings results on Monday, February, 26th. The technology company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.55) by $0.08.

What ETF holds Cogent Biosciences' stock?

Virtus LifeSci Biotech Clinical Trials ETF holds 17,467 shares of COGT stock, representing 1.07% of its portfolio.

What other stocks do shareholders of Cogent Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP) , Visa (V) , Viveve Medical (VIVE) , Red Violet (RDVT) , Freeport-McMoRan (FCX) , HP (HPQ) , Nutanix (NTNX) , OPKO Health (OPK) , STMicroelectronics (STM) and Actinium Pharmaceuticals (ATNM) .

How do I buy shares of Cogent Biosciences?

Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:COGT

Cogent Biosciences (COGT) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free COGT Stock Alerts

$6.71

+0.10 (+1.51%)

(As of 04/19/2024 ET)

Compare

Today's Range: $6.45
▼
$6.92
50-Day Range: $5.46
▼
$9.02
52-Week Range: $3.67
▼
$13.50

Volume: 1.52 million shs
Average Volume: 2.06 million shs
Market Capitalization: $641.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.67

Get Cogent Biosciences alerts:

Cogent Biosciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 103.7% Upside
$13.67 Price Target
Short Interest: Bearish
11.34% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.26
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.89) to ($1.71) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.66 out of 5 stars

Medical Sector

642nd out of 911 stocks

Pharmaceutical Preparations Industry

276th out of 412 stocks

4.4

Analyst's Opinion

Consensus Rating
Cogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cogent Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
11.34% of the outstanding shares of Cogent Biosciences have been sold short.
Short Interest Ratio / Days to Cover
Cogent Biosciences has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Cogent Biosciences has recently increased by 12.56%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cogent Biosciences does not currently pay a dividend.
Dividend Growth
Cogent Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for COGT.

1.8

News and Social Media Coverage

News Sentiment
Cogent Biosciences has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Cogent Biosciences this week, compared to 2 articles on an average week.
MarketBeat Follows
Only 1 people have added Cogent Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cogent Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.10% of the stock of Cogent Biosciences is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cogent Biosciences are expected to grow in the coming year, from ($1.89) to ($1.71) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cogent Biosciences is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cogent Biosciences is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cogent Biosciences has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Cogent Biosciences Stock (NASDAQ:COGT)

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

COGT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

COGT Stock News Headlines

April 18, 2024 | prnewswire.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)

April 14, 2024 | americanbankingnews.com

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 12, 2024 | americanbankingnews.com

Cogent Biosciences (NASDAQ:COGT) Trading Down 7.3%

April 9, 2024 | globenewswire.com

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

March 16, 2024 | finance.yahoo.com

COGT Apr 2024 7.500 call

March 14, 2024 | insidermonkey.com

5 Best Biotech Stocks To Buy Under $20

February 28, 2024 | finance.yahoo.com

COGT Reports Full Year 2023 Financial Results and Business Highlights

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 27, 2024 | msn.com

Baird Downgrades Cogent Biosciences (COGT)

February 26, 2024 | msn.com

Cogent Biosciences GAAP EPS of -$0.63

February 26, 2024 | globenewswire.com

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

February 23, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Cogent Biosciences as Bezuclastinib Showcases Strong Market Potential

February 23, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Lantheus (LNTH) and Ardelyx (ARDX)

February 22, 2024 | msn.com

Cogent Biosciences stock jumps on Phase 2 data for bezuclastinib

February 22, 2024 | globenewswire.com

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

February 22, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Cogent Biosciences Amid Positive Outlook for Bezuclastinib’s Efficacy and Safety

February 15, 2024 | finance.yahoo.com

Steven Cohen's Point72 Asset Management Bolsters Position in Cogent Biosciences

February 15, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Cogent Biosciences (COGT)

February 14, 2024 | seekingalpha.com

Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst

February 14, 2024 | finance.yahoo.com

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

February 14, 2024 | globenewswire.com

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

February 5, 2024 | finance.yahoo.com

Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting

January 9, 2024 | msn.com

Cogent Biosciences issues study updates on bezuclastinib, CGT4859

January 9, 2024 | finance.yahoo.com

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

January 2, 2024 | finance.yahoo.com

Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

December 22, 2023 | benzinga.com

Cogent Biosciences Stock (NASDAQ:COGT) Dividends: History, Yield and Dates

See More Headlines

Receive COGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/26/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:COGT
CUSIP: N/A
CIK: 1460329
Web: www.cogint.com
Phone: (617) 945-5576
Fax: N/A
Employees: 164
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.67
High Stock Price Target: $20.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +110.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-192,410,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -86.67%
Return on Assets: -58.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.09
Quick Ratio: 7.09

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.30 per share
Price / Book: 2.83

Miscellaneous

Outstanding Shares: 95,610,000
Free Float: 90,737,000
Market Cap: $621.47 million
Optionable: Optionable
Beta: 1.50

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Andrew R. Robbins M.B.A. (Age 48)
President, CEO & Director
Comp: $1.06M
Dr. John Edward Robinson Ph.D. (Age 49)
Chief Scientific Officer
Comp: $749.89k
Dr. Jessica Sachs M.D. (Age 49)
Chief Medical Officer
Comp: $773.92k
Mr. John L. Green C.A. (Age 44)
CPA, CFO & Principal Accounting Officer
Comp: $763.99k
Mr. Brad Barnett
Chief Technology Officer
Christi Waarich
Senior Director of Investor Relations
Mr. Evan D. Kearns J.D. (Age 44)
Chief Legal Officer & Corporate Secretary
Ms. Erin Schellhammer
Chief People Officer
Mr. Dana R. Martin Pharm.D.
Senior Vice President of Medical Affairs
Brad Fell
Senior Vice President of Chemistry

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

COGT Stock Analysis - Frequently Asked Questions

Should I buy or sell Cogent Biosciences stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" COGT shares.
View COGT analyst ratings or view top-rated stocks.
What is Cogent Biosciences' stock price target for 2024?: 7 brokerages have issued 1-year price targets for Cogent Biosciences' stock. Their COGT share price targets range from $8.00 to $20.00. On average, they expect the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 103.7% from the stock's current price.
View analysts price targets for COGT or view top-rated stocks among Wall Street analysts.
How have COGT shares performed in 2024?: Cogent Biosciences' stock was trading at $5.88 at the beginning of the year. Since then, COGT shares have increased by 14.1% and is now trading at $6.71.
View the best growth stocks for 2024 here.
Are investors shorting Cogent Biosciences?: Cogent Biosciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,840,000 shares, an increase of 12.6% from the March 15th total of 9,630,000 shares. Based on an average daily volume of 2,170,000 shares, the short-interest ratio is presently 5.0 days.
View Cogent Biosciences' Short Interest.
When is Cogent Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our COGT earnings forecast.

How were Cogent Biosciences' earnings last quarter?: Cogent Biosciences, Inc. (NASDAQ:COGT) posted its earnings results on Monday, February, 26th. The technology company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.55) by $0.08.
What ETF holds Cogent Biosciences' stock?: Virtus LifeSci Biotech Clinical Trials ETF holds 17,467 shares of COGT stock, representing 1.07% of its portfolio.
What other stocks do shareholders of Cogent Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ), Nutanix (NTNX), OPKO Health (OPK), STMicroelectronics (STM) and Actinium Pharmaceuticals (ATNM).
How do I buy shares of Cogent Biosciences?: Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:COGT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial